Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.


Related Content

Financings Of The Fortnight: IPOs Dominate Early 2014 With 13 Debuts In As Many Days
Deals Of The Week Looks At Pricing Conundrums
Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy
Ocular Gene Therapy Sees The Light
VC Enthusiasm For Gene Therapy Is Going Viral
uniQure Gets Its Groove On: An Interview With CEO Jörn Aldag
Deals of the Week: Is Botox On The Block?
Hemophilia In Transition: Can Next-Gen Products Wake A Sleepy Market?
Gene Therapy Firm AMT Forced To Go Private, Backed By Forbion
Chiesi/Cornerstone: Trading Ownership for Pipeline


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts